CytoDyn Inc.

  • Home
  • About CytoDyn
    • Overview
    • Our Mission
  • Our Science
  • Pipeline
  • Our Team
    • Leadership Team
    • Scientific Advisory Board
    • Board of Directors
    • Join our Team
  • Publications & Posters
  • Newsroom
    • Press Releases
  • Investors
    • Overview
    • Investor FAQs
    • Investor Update Calls
    • Annual Meeting of Stockholders
    • Warrant Exercise Inquiries
    • Restricted Stock Inquiries
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Overview
  • Investor FAQs
  • Investor Update Calls
  • Annual Meeting of Stockholders
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • News / Events
    • Overview
    • Press Releases
    • In The News
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Leadership Team
    • Presentations
    • Contacts
    • Company FAQs
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News / Events

  • Overview
  • Press Releases
  • In The News
  • IR Calendar
  • Email Alerts

CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024

Jun 27, 2024 8:30am EDT

CytoDyn to Host Webcast to Provide Company Update

May 28, 2024 8:30am EDT

May 2024 Letter to Shareholders

May 16, 2024 8:30am EDT

CytoDyn Announces FDA Has Lifted Clinical Hold

Feb 29, 2024 8:30am EST

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

Feb 01, 2024 8:30am EST

CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

Jan 29, 2024 8:30am EST

CytoDyn Announces Webcast to Provide Company Update

Dec 07, 2023 4:00pm EST

CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

Nov 21, 2023 8:30am EST

November 2023 Letter to Shareholders

Nov 03, 2023 4:02pm EDT

CytoDyn Announces Company Updates and Investment Community Update Webcast

Jul 11, 2023 4:05pm EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    Next
    • Email Alerts
    • Contacts
    • RSS News Feed
    © 2025 CytoDyn Inc. All Rights Reserved.
    Privacy Policy Legal Notice & Disclaimer Forward-Looking Statement Disclosure Sitemap